Cargando…

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer’s disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarez, X Anton, Alvarez, Irene, Martinez, Antia, Romero, Iria, Benito, Concha, Suarez, Irene, Mourente, Silvia, Fantini, Manuel, Figueroa, Jesús, Aleixandre, Manuel, Linares, Carlos, Muresanu, Dafin, Winter, Stefan, Moessler, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710915/ https://www.ncbi.nlm.nih.gov/pubmed/32640027 http://dx.doi.org/10.1093/ijnp/pyaa046

Ejemplares similares

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases
por: Alvarez, X. Anton, et al.
Publicado: (2016)

Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil
por: Alvarez, X. Anton, et al.
Publicado: (2022)

Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke
por: Bajenaru, O, et al.
Publicado: (2010)

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
por: Guekht, Alla, et al.
Publicado: (2017)

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
por: Muresanu, Dafin F., et al.
Publicado: (2016)

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial
por: Gharagozli, K, et al.
Publicado: (2017)

Role and Impact of Cerebrolysin for Ischemic Stroke Care
por: Mureșanu, Dafin F., et al.
Publicado: (2022)

Cerebrolysin administration reduces oxidative stress-induced apoptosis in limphocytes from healthy individuals
por: Formichi, Patrizia, et al.
Publicado: (2012)

Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study
por: Strilciuc, Stefan, et al.
Publicado: (2023)

Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery
por: Jianu, DC, et al.
Publicado: (2010)

Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial
por: Verisezan Rosu, Olivia, et al.
Publicado: (2023)

The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis
por: Mureșanu, Ioana Anamaria, et al.
Publicado: (2022)

Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials
por: Bornstein, Natan M., et al.
Publicado: (2017)

Cerebrolysin Attenuates Heat Shock Protein (HSP 72 KD) Expression in the Rat Spinal Cord Following Morphine Dependence and Withdrawal: Possible New Therapy for Pain Management
por: Sharma, Hari S, et al.
Publicado: (2011)

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
por: Rockenstein, Edward, et al.
Publicado: (2014)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50–60 nm) Nanoparticles
por: Sharma, Hari Shanker, et al.
Publicado: (2023)

The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury
por: Birle, Codruta, et al.
Publicado: (2020)

Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin
por: Onose, G, et al.
Publicado: (2009)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Effects of cerebrolysin on nerve growth factor system in the aging rat brain
por: Stepanichev, Mikhail, et al.
Publicado: (2017)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

In memoriam: Professor Ovidiu Alexandru Bajenaru (1957-2020)
por: Muresanu, Dafin
Publicado: (2020)

2021: New horizons in neurorehabilitation
por: Muresanu, Dafin
Publicado: (2021)

Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation
por: Martinez, RM
Publicado: (2017)

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis
por: Jarosz, Konrad, et al.
Publicado: (2023)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Brain recovery – towards an unified theory
por: Mureşanu, Dafin F
Publicado: (2010)

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial
por: Chen, Yun, et al.
Publicado: (2019)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer’s disease and chronic obstructive pulmonary disease: a retrospective observational study
por: Cao, Yangyi, et al.
Publicado: (2020)

Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats
por: Georgy, Gehan S., et al.
Publicado: (2013)

Role of Cerebrolysin(®) in Rehabilitation in Ischemic Stroke: A Case Report
por: Chanubol, Ratanapat, et al.
Publicado: (2021)

Cerebrolysin Use in Patients with Liver Damage—A Translational Study
por: Morega, Shandiz, et al.
Publicado: (2022)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

The Silver Lining in a Time of Crisis: The Foundation of the Society for the Study of Neuroprotection and Neuroplasticity (SSNN) Conference Proceedings Go Virtual
por: Muresanu, Dafin, et al.
Publicado: (2020)

New evidence for the pharmacological intervention promoting neurorecovery after stroke: results from the joint EAN-EFNR guidelines
por: Muresanu, Dafin, et al.
Publicado: (2021)

Continuing the Journey: The Second Edition of the Neurotrauma Treatment Simulation Center (NTSC)
por: Chira, Diana, et al.
Publicado: (2023)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sv2ce5absm17kcinl936t4frk